Bausch Health Companies vs Viatris
BHC and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and VTRS compare
Viatris is the larger company, worth 7.1 times as much as Bausch Health Companies ($21.9B against $3.1B).
Bausch Health Companies grew revenue faster over the last twelve months (10.1% versus 4.4% for Viatris).
Viatris pays a dividend yielding 2.5%; Bausch Health Companies does not pay one.
Bausch Health Companies scores higher on the StockData Score (7 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $21.9B |
| Share price | $8.20 | $19.04 |
| Change, 1 year | 39.0% | 85.3% |
| Change, 5 years | −70.7% | 38.6% |
| Beta (5Y) | 1.05 | 0.87 |
| Employees | 20K | 30K |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/S | 0.3× (better) | 1.5× |
| EV/EBITDA | 11.2× (better) | 12.6× |
| P/FCF | 2.1× (better) | 11.2× |
| FCF yield | 46.7% (better) | 8.9% |
| Fair value | $24.85 | $20.87 |
| Margin of safety | 67.0% (better) | 8.8% |
| Growth | ||
| Revenue growth (TTM) | 10.1% (better) | 4.4% |
| Revenue growth, 5Y average | 5.0% (better) | 3.7% |
| Net income growth (TTM) | −1220% | – |
| EPS growth (TTM) | −1238% | – |
| Profitability | ||
| Gross margin | – | 34.8% |
| Operating margin | 8.1% (better) | −0.59% |
| Net margin | −10.1% | – |
| FCF margin | 13.2% | 13.3% (better) |
| Return on invested capital | 3.8% | – |
| Financial health | ||
| Net debt / EBITDA | 9.20 | 4.59 (better) |
| Interest coverage | 0.5× (better) | −0.2× |
| Current ratio | 1.44 | 1.58 (better) |
| Altman Z-score | 0.11 | 1.16 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.5% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 1.4% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 63.4% | 91.5% |
| Held by insiders | 31.5% | 0.36% |
| Insider net buying, 12 months | $15.1M (better) | −$1.1M |
| Superinvestors holding | 1 | 3 (better) |
| Short interest, % of float | 3.3% | 3.7% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.